Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study

cafead

Administrator
Staff member
  • cafead   Aug 27, 2024 at 11:32: AM
via The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to researchers.

article source
 

<